Health · Medical Research · 1 hr ago
Daraxonrasib combination shows early promise in pancreatic cancer trial
A daraxonrasib combination is showing early promise in a trial involving people with pancreatic cancer.
The drug is a KRAS inhibitor that targets certain mutations called RAS, which drive tumour growth in most pancreatic cancers.
A doctor involved in the trial said researchers are seeing more tumour responses, deeper responses and nearly twice as long a period of disease control.
The results may point to longer survival, but they do not yet establish that patients will live longer.
Pancreatic cancer is diagnosed in about 11,500 people in Britain each year, and around 10,200 die from it, according to Cancer Research UK.
Researchers say longer trials are vital because tumours can return even when scans show no sign of cancer.
The drug may also be relevant to other cancers with similar mutations, but its effects there remain uncertain.
Early results from a pancreatic cancer trial suggest combining daraxonrasib with another treatment may improve tumour responses and disease control.
Daraxonrasib is a KRAS inhibitor that targets certain RAS mutations, which drive tumour growth in most pancreatic cancers.
Researchers said longer trials and follow-up are needed to determine whether the treatment improves survival.
The findings are being presented to doctors at the EORTC cancer conference.
About 11,500 people are diagnosed with pancreatic cancer in Britain each year, and around 10,200 die from it.
- Who
- Researchers involved in the trial, including Dr Wungki Park, reported the results.
- What
- Early results suggest a combined treatment including daraxonrasib may improve tumour responses and disease control.
- When
- The results were reported on 20 November 2026.
- Where
- The trial’s location is not stated. The findings are being presented at a European cancer conference called EORTC.
- Why
- Daraxonrasib targets certain RAS mutations that drive tumour growth in most pancreatic cancers.
This story does not have two clearly opposing sides.
The BBC reported early results from the pancreatic cancer trial.
The findings are being presented to other doctors.
- Drug
- Daraxonrasib, a KRAS inhibitor
- Trial finding
- Near doubling in duration of disease control, according to Dr Wungki Park
- Britain diagnoses
- 11,500 pancreatic cancer cases each year
- Britain deaths
- Around 10,200 pancreatic cancer deaths each year
- Trial follow-up
- Researchers said longer trials and results were vital
What people are saying
We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival.
These results are exciting because they show the combined treatment could potentially significantly improve patients' overall survival, as well as the time before tumours start to grow again.
I would hope that the early success that we are beginning to see in pancreatic cancer can also be rolled out to other cancers.
Cancer can come back and even if scans show there is no sign of it, you don't necessarily know you are cancer-free until more time has passed.